In:
Mediators of Inflammation, Hindawi Limited, Vol. 2019 ( 2019-06-26), p. 1-9
Abstract:
Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF ( n = 22 ) or fingolimod ( n = 44 ) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1 CM cells (relapsed: 11.60 ± 4.17 % vs . nonrelapsed: 9.25 ± 3.17 % , p 〈 0.05 ) and Th1Th17 CM cells (relapsed: 15.65 ± 6.15 % vs . nonrelapsed: 10.14 ± 4.05 % , p 〈 0.01 ) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17 CM (CD4 + CCR7 + CD45RA - CCR6 + CXCR3 + ) cells 〉 11.48 % had a 50% relapse-free survival compared to patients with Th1Th17 CM cells 〈 11.48 % whose relapse-free survival was 88% ( p = 0.013 , log-rank test). Additionally, a high percentage of Th1Th17 CM cells was also found in patients with MRI activity (MRI activity: 14.02 ± 5.87 % vs . no MRI activity: 9.82 ± 4.06 % , p 〈 0.01 ). Our results suggest that the percentage of Th1Th17 CM lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment.
Type of Medium:
Online Resource
ISSN:
0962-9351
,
1466-1861
DOI:
10.1155/2019/8147803
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2019
detail.hit.zdb_id:
2008065-7